| SMARCD3, also known as BAF60c, is a core subunit of the mammalian SWI/SNF (BAF) ATP-dependent chromatin remodeling complex that enables nucleosome repositioning and gene activation by stabilizing interactions between the BRG1 or BRM ATPase and transcription factors during development and metabolism. This protein, which is about 530 amino acids long, contains two SWI3-like ATPase-association domains that bind the ATPase motor non-covalently, flanked by intrinsically disordered regions that allow for modular assembly into canonical BAF, neural progenitor BAF (npBAF), or specialized lipoBAF complexes with ARID1A or ARID1B, SS18, and tissue-specific partners. SMARCD3's primary function is to integrate signals from nuclear receptors such as RAR, PPAR gamma, and LXR, as well as lineage transcription factors like FOXA1, recruiting SWI/SNF to enhancers and promoters to slide or evict nucleosomes, deposit active histone marks like H3K27 acetylation, and drive transcription of genes involved in skeletal and cardiac muscle differentiation, lipogenesis through SREBP1, ACC, and FASN, glucose homeostasis via DEPTOR-AKT signaling, and epithelial-mesenchymal transition. In the lipoBAF complex, SMARCD3 senses feeding and insulin signals to remodel chromatin at lipogenic gene loci, increasing triglyceride production and repressing catabolic pathways, while in heart and muscle tissue, it partners with GATA4 and MEF2C to regulate genes essential for sarcomere and cytoskeletal organization during congenital morphogenesis. Dysregulation of SMARCD3 contributes to medulloblastoma dissemination, especially in Group 3 tumors through Reelin and H3K27 trimethylation, pancreatic cancer therapy resistance, abdominal aortic aneurysms, and poor outcomes across various solid tumors. |
